Skip to main content
MIRM
NASDAQ Life Sciences

Mirum Q3 Sales $185.7M, Lifts 2026 Product Sales Guidance to $715-720M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$87.03
Mkt Cap
$5.651B
52W Low
$63.232
52W High
$130
52W Position info
38% above low
Off High info
33% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MIRM sits 38% above its 52-week low of $63.232.

Summary

Mirum reported Q3 2026 net product sales of $185.7 million and raised full-year product sales guidance to $715-720 million, while quarterly operating expenses of $245.5 million left a $40.8 million net loss.


Key Events · Earnings and Guidance · MIRM

  • Q3 Product Sales Reach $185.7M

    Third quarter 2026 global net product sales were $185.7 million versus $133.0 million in the year-earlier quarter, with LIVMARLI contributing $133.4 million (45% growth) and Bile Acid Medicines $52.3 million (28% growth).

  • 2026 Guidance Raised to $715-720M

    Full-year net product sales guidance was increased to $715 million to $720 million on the back of the Q3 result.

  • Quarterly Net Loss of $40.8M

    Total operating expenses of $245.5 million, including $13.5 million of non-recurring acquired IPR&D, drove a $40.8 million net loss for the quarter.

  • Convertible Notes Cut by $20M

    Mirum repurchased $20.0 million principal of its 4.00% convertible senior subordinated notes due 2029, roughly 25% of the outstanding notes; cash, equivalents and investments stood at $500.5 million at September 30, 2026.


Analysis · MIRM · Life Sciences

What's new here is the quarter's revenue and the raised full-year range; the pipeline recap (ATEBRIOZ approval, AZURE-1, EXPAND) was already disclosed in September and October filings. Sales of $185.7 million against $133.0 million a year earlier put the company on pace for the higher guidance, and the balance sheet still carries $500.5 million of cash and investments after a $20.0 million convertible note repurchase. Cost is the offset: operating expenses of $245.5 million produced a $40.8 million quarterly net loss, so the growth story still runs at a loss while the company funds five planned approvals and label expansions.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MIRM was trading at $87.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $63.23 to $130.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MIRM - Latest Insights

MIRM
Nov 10, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $93.18
Real-time Price: $92.51 info
Change: -$0.670 (-0.72%) info
Market Cap: $6.038B info
MIRM
Nov 10, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
9
Price at Filing: $93.18
Real-time Price: $92.51 info
Change: -$0.670 (-0.72%) info
Market Cap: $6.038B info
MIRM
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $92.51 info
Change: +$5.48 (+6%) info
Market Cap: $6.038B info
MIRM
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $92.51 info
Change: +$5.48 (+6%) info
Market Cap: $6.038B info
MIRM
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $80.15
Real-time Price: $92.51 info
Change: +$12.36 (+15%) info
Market Cap: $6.038B info